Semaglutide vs Tirzepatide for Sleep Apnea
Sleep apnea affects millions of adults with obesity. Tirzepatide has a specific FDA indication, but how do the two medications actually compare?
Medical Disclaimer: Do not adjust CPAP therapy without consulting your sleep medicine provider. This comparison is for informational purposes only.
Obstructive sleep apnea (OSA) affects an estimated 30 million Americans and is strongly linked to obesity. Weight loss is the most effective non-surgical treatment, and tirzepatide now has FDA approval specifically for OSA in adults with obesity. But how does it compare to semaglutide?
The SURMOUNT-OSA Trial
The SURMOUNT-OSA study was a landmark trial specifically evaluating tirzepatide for sleep apnea:
- Patients with moderate-to-severe OSA and BMI 30+ were randomized to tirzepatide or placebo
- Tirzepatide reduced AHI (apnea-hypopnea index) by approximately 50%
- About 43% of patients achieved AHI below the clinical threshold for moderate OSA
- Average weight loss was approximately 20%
- Improvements in oxygen saturation, sleep quality, and daytime sleepiness were significant
Comparison Table
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| FDA approved for OSA | No | Yes (2024) |
| Dedicated OSA trial | No | Yes (SURMOUNT-OSA) |
| Average weight loss | ~15% | ~20% |
| Expected AHI reduction | ~30-40% (estimated) | ~50% (proven) |
| Insurance coverage for OSA | Unlikely | Possible with Zepbound |
The Bottom Line
Our Assessment
Tirzepatide has the clear advantage for sleep apnea: FDA approval, dedicated trial data, and greater average weight loss. If OSA is a primary concern, tirzepatide should be your first-line choice. Semaglutide also improves sleep apnea through weight loss, but lacks the specific evidence base.
Frequently Asked Questions
Can GLP-1 cure sleep apnea?
GLP-1 medications can significantly improve and in some cases resolve obstructive sleep apnea through weight loss. The SURMOUNT-OSA trial showed tirzepatide reduced AHI (apnea-hypopnea index) by approximately 50%. Whether it fully resolves depends on severity and other contributing factors like facial anatomy.
How much weight loss to improve sleep apnea?
Research shows that 10-15% weight loss can reduce AHI by 50% or more. Many patients see meaningful improvement with just 5-10% weight loss. Both semaglutide and tirzepatide can achieve this level of weight loss for most patients.
Can I stop using CPAP after losing weight on GLP-1?
Potentially, but do not stop CPAP without a follow-up sleep study. Even significant weight loss does not always fully resolve sleep apnea. Your sleep medicine provider should reassess your AHI after weight loss to determine if CPAP is still needed.
Which GLP-1 is FDA-approved for sleep apnea?
Tirzepatide (Zepbound) received FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity in 2024, based on the SURMOUNT-OSA trials. Semaglutide does not have this specific indication, though it is also effective for weight loss that improves sleep apnea.
Breathe Easier, Sleep Better
Trimi offers affordable GLP-1 treatment to help improve sleep apnea through effective weight loss.
Get Started TodayMore on Micro-Comparisons
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).